Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Filipits, M; Rudas, M; Heinzl, H; Jakesz, R; Kubista, E; Lax, S; Schippinger, W; Dietze, O; Greil, R; Stiglbauer, W; Kwasny, W; Nader, A; Stierer, M; Gnant, MF; Austrian Breast and Colorectal Cancer Study Group.
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Clin Cancer Res. 2009; 15(18):5888-5894
Doi: 10.1158/1078-0432.CCR-09-0728
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Schippinger Walter
- Study Group Mitglieder der Med Uni Graz:
- Bauernhofer Thomas
- Smola Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: Previously, we have shown that p27 may be a potential predictive biomarker for the selection of premenopausal women with early-stage hormone-responsive breast cancer for adjuvant endocrine therapy. The purpose of the present study was to assess the clinical relevance of p27 expression in postmenopausal hormone receptor-positive breast cancer patients who were treated with adjuvant tamoxifen therapy. Experimental Design: We determined the expression of p27 by immunohistochemistry in the surgical specimens of breast carcinoma patients who had been enrolled in Austrian Breast and Colorectal Cancer Study Group Trial 06 and received tamoxifen for 5 years. Early relapse and death within the first 5 years of follow-up were analyzed using Cox models adjusted for clinical and pathologic factors. Results: p27 expression was high (> 70% p27-positive tumor cells) in 252 of 483 (52%) tumor specimens and was associated with favorable outcome of the patients. Women with high p27 expression had a significantly longer disease-free survival (adjusted hazard ratio for relapse, 0.22; 95% confidence interval, 0.11-0.42; P < 0.001) and overall survival (adjusted hazard ratio for death, 0.39; 95% confidence interval, 0.21-0.72; P = 0.002) as compared with women with low p27 expression. Conclusion: Low p27 expression independently predicts early relapse and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen for 5 years. (Clin Cancer Res 2009;15(18):5888-94)
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antineoplastic Agents, Hormonal - administration and dosage Antineoplastic Agents, Hormonal - therapeutic use
- Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - surgery
- Chemotherapy, Adjuvant -
- Cyclin-Dependent Kinase Inhibitor p27 - biosynthesis
- Female -
- Follow-Up Studies -
- Humans -
- Immunohistochemistry -
- Kaplan-Meier Estimate -
- Middle Aged -
- Multivariate Analysis -
- Postmenopause -
- Predictive Value of Tests -
- Prognosis -
- Receptors, Progesterone - analysis Receptors, Progesterone - genetics
- Recurrence -
- Survival Analysis -
- Survival Rate -
- Tamoxifen - administration and dosage Tamoxifen - therapeutic use
- Treatment Outcome -